P
BiomX Inc.
PHGECIK 0001739174NYSENon-AcceleratedSmaller ReportingBiological Products, (No Diagnostic Substances)DelawareFY ends Dec 31
Period
FY 2025
Revenue
—
Net Income
$-36.20M
Total Assets
—
Equity
—
Shares Out
10.15M
Op. Cash Flow
$-26.39M
Business
BiomX Inc. is a clinical-stage product discovery company developing natural and engineered bacteriophage-based therapies that target and kill specific pathogenic bacteria associated with chronic diseases. It offers fixed phage cocktail therapies and personalized phage treatments matched via proprietary phage susceptibility testing (PST), and advances candidates such as BX004 (Pseudomonas) and BX211 (Staphylococcus aureus). Its operations center on R&D platforms—BOLT for cocktail discovery and PST for personalized matching—supported by manufacturing, IP licensing and development programs. The company conducts clinical trials and regulatory interactions across the United States, Europe and other international jurisdictions, and uses a hybrid model of in-house development and third-party manufacturing, testing and distribution partners.
Summary from filing dated 2025-03-25
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development (R&D) expenses, net | 21 | 25 | 17 | 16 | 23 | |
| General and administrative expenses | 10 | 12 | 9 | 9 | 11 | |
| Gain from early lease termination | −3 | — | — | — | — | |
| Goodwill impairment | — | 801,000 | — | — | — | |
| IPR&D impairment | 12 | 3 | — | — | — | |
| Other long-lived assets impairment | 2 | 4 | — | — | — | |
| Operating loss | 41 | 45 | 25 | 27 | 35 | |
| Other expense (income) | 93,000 | −2 | −357,000 | −134,000 | — | |
| Interest expenses | 20,000 | 873,000 | 2 | — | — | |
| Finance expense , net | 724,000 | 919,000 | — | — | — | |
| Income from change in fair value of warrants | −6 | −26 | — | — | — | |
| Loss before tax | 36 | 18 | 26 | 28 | 36 | |
| Tax expenses | 7,000 | 13,000 | 23,000 | 65,000 | 67,000 | |
| Net Loss | 36 | 18 | 26 | 28 | 36 | |
| Basic loss per share of Common Stock (in Dollars per share) | 22.19 | 25.37 | 5.1 | 0.95 | 1.39 | |
| Diluted loss per share of Common Stock (in Dollars per share) | 22.19 | 58.31 | 5.1 | 0.95 | 1.39 | |
| Weighted average number of shares used in computing basic loss per share of Common Stock (in Shares) | 2 | 698,870 | 5 | 30 | — | |
| Weighted average number of shares used in computing diluted loss per share of Common Stock (in Shares) | 2 | 757,749 | 5 | 30 | 26 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2024 2024-07-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 4 | 17 | — | 15 | 31 | |
| Restricted cash | 595,000 | 958,000 | — | 957,000 | 962,000 | |
| Property and equipment, held for sale | 157,000 | — | — | — | — | |
| Other current assets | 463,000 | 3 | — | 2 | 3 | |
| Total current assets | 6 | 21 | — | 18 | 37 | |
| Non-current restricted cash | — | 161,000 | — | — | — | |
| Operating lease right-of-use assets | — | 5 | — | 3 | 4 | |
| Property and equipment, net | — | 5 | — | 4 | 5 | |
| In-process Research and development (IPR&D) asset | 208,000 | 12 | — | — | — | |
| Total non-current assets | 208,000 | 23 | — | 7 | 9 | |
| Total Assets | 6 | 43 | — | 25 | 46 | |
| Trade account payables | 3 | 2 | — | 1 | 820,000 | |
| Current portion of lease liabilities | 1 | 1 | — | 666,000 | 687,000 | |
| Other account payables | 2 | 5 | — | 3 | 2 | |
| Total current liabilities | 6 | 8 | — | 11 | 8 | |
| Operating lease liabilities, net of current portion | — | 8 | — | 3 | 4 | |
| Other liabilities | — | 77,000 | — | 155,000 | 188,000 | |
| Warrants | 706,000 | 2 | — | — | — | |
| Total non-current liabilities | 706,000 | 11 | — | 11 | 17 | |
| Commitments and Contingencies (Note 8) | — | — | — | — | — | |
| Preferred Stock, $0.0001 par value; Authorized - 1,000,000 shares as of December 31, 2025 and December 31, 2024. Issued and outstanding 147,512 as of December 31, 2025 and 147,735 shares as of December 31, 2024. | 19 | 19 | — | — | — | |
| Common stock, $0.0001 par value (Common Stock); Authorized - 750,000,000 shares as of December 31, 2025 and December 31, 2024. Issued and outstanding 1,593,703 and 1,023,010 as of December 31, 2025 and December 31, 2024, respectively. (*) | 7,000 | 6,000 | — | 3,000 | 2,000 | |
| Additional paid in capital | 197 | 186 | — | 166 | 158 | |
| Accumulated deficit | −217 | −181 | −181 | −163 | −137 | |
| Total Stockholders equity (capital deficiency) | −1 | 24 | — | 3 | 21 | |
| Total liabilities and stockholders equity | 6 | 43 | — | 25 | 46 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation | 3 | 2 | 871,000 | — | 3 | |
| Stock-based compensation | 2 | 2 | 1 | 2 | 3 | |
| Finance expense (income), net | 256,000 | −435,000 | — | −842,000 | 25,000 | |
| Revaluation of contingent consideration | −77,000 | −78,000 | −33,000 | — | — | |
| Income from change in fair value of warrants | −6 | −26 | — | — | — | |
| Private Placement Warrants issuance cost | — | 732,000 | — | — | — | |
| Changes in contract liability | — | −2 | — | — | — | |
| Loss from sale and disposal of fixed assets, net | 205,000 | 221,000 | 71,000 | — | — | |
| Other current assets | 2 | 842,000 | 819,000 | — | — | |
| Trade account payables | 1 | −3 | 556,000 | −2 | 427,000 | |
| Other account payables | −3 | −984,000 | 1 | −3 | 665,000 | |
| Net change in operating leases | −74,000 | 316,000 | −93,000 | −106,000 | 2,000 | |
| Net cash used in operating activities | −26 | −37 | −21 | −29 | −28 | |
| Cash and restricted cash acquired from the APT acquisition | — | 663,000 | — | — | — | |
| Purchase of property and equipment | −2,000 | −30,000 | −50,000 | −112,000 | −4 | |
| Proceeds from sale of property and equipment | 110,000 | 82,000 | 1,000 | 5,000 | 4,000 | |
| Net cash provided by investing activities | 108,000 | 715,000 | 2 | −2 | 16 | |
| Issuance of Common Stock under February 2025 SPA | 996,000 | — | 7 | 19,000 | 5 | |
| February 2025 SPA issuance costs | −118,000 | — | — | — | — | |
| Issuance of Common Warrants under February 2025 SPA | 5 | — | — | — | — | |
| Issuance of Common Stock under Inducement Letter Agreements | 6 | — | — | — | — | |
| Pre-Funded Warrants exercise | 2,000 | 6,000 | — | — | — | |
| Issuance of Common Stock under Open Market Sales Agreement, net of issuance costs | 1 | 19,000 | — | — | — | |
| Repayment of long-term debt | — | −11 | −4 | — | — | |
| Issuance of Private Placement Warrants under March 2024 PIPE | — | 29 | — | — | — | |
| Issuance of Redeemable Convertible Preferred Shares under March 2024 PIPE | — | 21 | — | — | — | |
| March 2024 PIPE issuance costs | — | −918,000 | — | — | — | |
| Net cash provided by financing activities | 13 | 38 | 3 | 292,000 | 37 | |
| Increase (decrease) in cash and cash equivalents and restricted cash | −13 | 2 | −16 | −31 | — | |
| Effect of exchange rate changes on cash and cash equivalents and restricted cash | 73,000 | 1,000 | 6,000 | 106,000 | −25,000 | |
| Cash paid for interest | 20,000 | 1 | 2 | 2 | 399,000 | |
| Taxes paid in Israel | 7,000 | 13,000 | 54,000 | 65,000 | 67,000 | |
| Lease liability and Operating lease right-of-use asset remeasurement | 2 | — | — | — | — | |
| Derecognition of right-of-use asset as a result of operating lease termination | 2 | — | — | — | — | |
| Derecognition of lease liability as a result of operating lease termination | 5 | — | — | — | — | |
| Property and equipment purchases included in accounts payable | — | 1,000 | 5,000 | — | — | |
| Issuance cost from March 2024 PIPE | — | 1 | — | — | — | |
| Issuance of Common Stock under the APT acquisition | — | 3 | — | — | — | |
| Issuance of Redeemable Convertible Preferred Shares under the APT acquisition | — | 13 | — | — | — | |
| Issuance of Merger Warrants under the APT acquisition | — | 200,000 | — | — | — | |
| Redeemable Convertible Preferred Shares conversion into shares of Common Stock | 28,000 | 14 | — | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro